TABLE 3.
Pharmacokinetic measures for ofloxacin (20 mg/kg) in children receiving treatment or prevention for multidrug-resistant tuberculosis, by age, HIV status, nutritional status, and administration methoda
| Parameter | No. of children | Cmax (μg/ml) | P value | AUC0–8 (μg · h/ml) | P value | No. of children | AUC0–24 (μg · h/ml) | P value | t1/2 (h) | P value |
|---|---|---|---|---|---|---|---|---|---|---|
| Age group | ||||||||||
| 0 to <2 yr | 24 | 10.43 (1.96) | 45.9 (8.8) | 23 | 63.9 (15.3) | 3.01 (0.53) | ||||
| 2 to <5 yr | 39 | 8.52 (2.37) | 43.8 (12.0) | 35 | 66.5 (20.9) | 3.52 (0.75) | ||||
| ≥5 yr | 22 | 8.18 (2.01) | <0.001 | 43.1 (8.9) | 0.632 | 14 | 71.7 (17.8) | 0.473 | 4.18 (1.22) | <0.001 |
| HIV status | ||||||||||
| HIV infected | 11 | 8.42 (1.51) | 42.5 (9.0) | 9 | 63.4 (16.4) | 3.35 (0.59) | ||||
| Not HIV infected | 74 | 9.05 (2.44) | 0.404 | 44.4 (10.6) | 0.560 | 63 | 67.1 (19.0) | 0.579 | 3.51 (0.93) | 0.614 |
| WAZ | ||||||||||
| <−2.0 | 18 | 8.94 (2.35) | 42.7 (11.4) | 15 | 61.0 (20.1) | 3.06 (0.49) | ||||
| ≥−2.0 | 67 | 8.98 (2.35) | 0.953 | 44.6 (10.1) | 0.498 | 57 | 68.2 (18.1) | 0.190 | 3.60 (0.94) | 0.004 |
| Administration | ||||||||||
| Whole | 11 | 7.87 (1.67) | 42.2 (10.6) | 8 | 72.4 (23.4) | 4.32 (1.45) | ||||
| Crushed | 72 | 9.16 (2.40) | 0.089 | 44.6 (10.4) | 0.481 | 62 | 66.1 (18.1) | 0.375 | 3.39 (0.76) | 0.114 |
a
HIV status, nutritional status, and administration method comparisons were generated using t tests; age group comparisons were generated using one-way analyses of variance (ANOVAs); all values are presented as means (standard deviations). A total of 85 children participated in the study.